Patient Recruitment Completed for Pivotal Study of Remoxy
Posted on: Friday, 13 July 2007, 12:13 CDT
Durect has completed patient recruitment for its Phase III study with Remoxy, an abuse resistant pain medicine currently under development.
This randomized, double-blinded, placebo-controlled study enrolled patients in the US with moderate-to-severe osteoarthritic pain. Following a titration period, patients were randomized to either twice-daily Remoxy (10-80 mg daily) or placebo for 12 weeks.
The primary endpoint is change in pain scores during the treatment period. Top line results of this study are expected in the fourth quarter of 2007, after the last patient completes the three-month treatment period.
Remoxy is based on Durect's patented Oradur technology incorporating the opioid oxycodone.
Source: Datamonitor
Related Articles
- Cheap Drug Relieves Fibromyalgia Pain In Pilot Study
- Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
- Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
- New Study: Pine Bark Significantly Reduces Menstrual Pain
- Study Finds Naturopathic Care for Chronic Low-Back Pain to Be Efficacious, Cost-Effective
- Knee Pain? An Exclusive Study Engineers Cartilage to Match Patient's Own Tissue
- Doc Defends Pain Supplements, Slams Study
- Pain and King Begin Remoxy Phase 3 Study
- Women With Low Estrogen Levels More Sensitive to Pain, Brain Activity Readings Confirm
- Local Doctors OK Celebrex; The FDA is Wary About the Pain Medication After Studies Linked It to Heart Problems.
 |
 |
User Comments (0)
RSS Feeds